FDA advisors quit after approval of Alzheimer's medicine

On Monday, US authorities defied an external panel by approving Biogen's Alzheimer's treatment. Now, several of the participants are stepping down.

BY RITZAU, TRANSLATED BY CATHERINE BRETT

Published: 11.06.21 at 10:45

Three members of an outside panel that advises the US Food and Drug Administration (FDA) have quit over the past few days.

This is in protest over the decision made by the authority to approve Aduhelm, an Alzheimer's drug developed by Biogen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Foto: Russell Cheyne/Reuters/Ritzau Scanpix

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Germany orders 40,000 monkeypox vaccines from Bavarian Nordic

Foto: Elizabeth Dalziel/AP/Ritzau Scanpix

The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.

New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"

Morten Søgaard is moving from one US coast to another, as he makes a switch from Pfizer to Astellas Gene Therapies | Foto: Jens Panduro

Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.

Rumored purchase of GN Group could mean divestment of hearing aid division, says media

Foto: GN Store Nord / PR

Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.

EMA publishes new plan to support antibiotic development

Foto: Peter Dejong/AP/Ritzau Scanpix

Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.

Further reading

Related articles